Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Recapitulate the Predilection of Breast Cancer Patients to Doxorubicin–Induced Cardiotoxicity
By P. Burridge, Y. F. Li, Elena Matsa, Haodi Wu, S. Ong, Arun Sharma, Alexandra Holmström, Alex C. Y. Chang, Michael Coronado, Antje D. Ebert and 7 more. Nature Medicine, 2016
659 citations recorded by the source corpus.
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but it causes a dose-related cardiotoxicity that can lead to heart failure in a subset of patients. At present, it is not possible to predict which patients will be affected by doxorubicin-induced cardiotoxicity (DIC). Here we demonstrate that patient-specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to DIC of individual patients at the cellular level. hiPSC-CMs derived from individuals with breast cancer who experienced DIC were consistently more sensitive to doxorubicin toxicity than hiPSC-CMs from patients who did not experience DIC, with decreased cell viability, impaired mitochondrial and metabolic function, impaired calcium handling, decreased antioxidant pathway activity, and increased reactive oxygen species production. Taken together, our data indicate that hiPSC-CMs are a suitable platform to identify and characterize the genetic basis and molecular mechanisms of DIC.
Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/d5d88edb1f81cf00a7d0630586f525dee53ccbb4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Cardiology and Cardiovascular Medicine
In Molecular Biology
- Joseph Loscalzo
- Albert-László Barabási
- Feixiong Cheng
- Olaf Sporns
- Alessandro Vespignani
- Mark Newman
- Marinka Zitnik
- Marc Barthelemy
Citations in the corpus
- Network-based approach to prediction and population-based validation of in silico drug repurposing (2018, background): “Focusing on just single targets results in failure to anticipate off-target toxicity, unintended beneficial effects, or multiple target interactions leading to suboptimal efficacy (6-10).”